A Rare Case of Missing Primary in Metastatic Renal Cell Carcinoma

被引:0
作者
Kapoor, Ankita [1 ]
Khushalani, Nikhil [2 ]
Gandhi, Shipra [3 ]
机构
[1] Rochester Gen Hosp, Internal Med, Rochester, NY 14621 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol, Tampa, FL USA
[3] Roswell Pk Canc Inst, Oncol, Buffalo, NY USA
关键词
renal cell carcinoma; sunitinib; radiographic primary; metastatic rcc; papillary rcc; DIAGNOSIS;
D O I
10.7759/cureus.8637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal cell carcinoma (RCC) can present with a myriad of clinical symptoms and signs. It is also notorious for its initial presentation with distant metastasis. We report a case of a 42-year-old male diagnosed with papillary RCC (PRCC) presenting with pleural and nodal metastases in the absence of a radiographically-detected tumor primary. PRCC was diagnosed on immunohistochemical analysis of the tissue from the pleura and mediastinal lymph nodes and confirmed by gene expression profiling studies. As per treatment guidelines for metastatic RCC, the patient was started on sunitinib with evidence of disease progression after two cycles and palliative care approach was recommended due to rapidly declining performance status. Prospective data on the optimal management of metastatic PRCC are lacking, but drugs used are similar to the treatment of clear cell carcinomas (vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors) and checkpoint inhibitors. Further molecular study of these rare tumors is warranted to detect drivers of oncogenesis and identify targets for therapeutic intervention.
引用
收藏
页数:12
相关论文
共 20 条
[1]   Distribution of metastatic sites in renal cell carcinoma: a population-based analysis [J].
Bianchi, M. ;
Sun, M. ;
Jeldres, C. ;
Shariat, S. F. ;
Trinh, Q. -D. ;
Briganti, A. ;
Tian, Z. ;
Schmitges, J. ;
Graefen, M. ;
Perrotte, P. ;
Menon, M. ;
Montorsi, F. ;
Karakiewicz, P. I. .
ANNALS OF ONCOLOGY, 2012, 23 (04) :973-980
[2]   Systemic Therapy for Metastatic Renal-Cell Carcinoma [J].
Choueiri, Toni K. ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :354-366
[3]   Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases [J].
Chu, PG ;
Wu, E ;
Weiss, LM .
MODERN PATHOLOGY, 2000, 13 (09) :962-972
[4]   Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Escudier, B. ;
Porta, C. ;
Schmidinger, M. ;
Rioux-Leclercq, N. ;
Bex, A. ;
Khoo, V. ;
Grunwald, V. ;
Gillessen, S. ;
Horwich, A. .
ANNALS OF ONCOLOGY, 2019, 30 (05) :706-720
[5]   Recent progress in the management of advanced renal cell carcinoma [J].
Garcia, Jorge A. ;
Rini, Brian I. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (02) :112-125
[6]  
Kawakita M, 1985, Hinyokika Kiyo, V31, P463
[7]  
Koga S, 2000, ANTICANCER RES, V20, P1939
[8]   Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis. [J].
Koshkin, Vadim S. ;
Barata, Pedro C. ;
Vogelzang, Nicholas J. ;
Pal, Sumanta K. ;
Hsu, Joann ;
Allman, Kimberly D. ;
Gilligan, Timothy D. ;
Rini, Brian I. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9]   Renal cell cancer histological subtype distribution differs by race and sex [J].
Lipworth, Loren ;
Morgans, Alicia K. ;
Edwards, Todd L. ;
Barocas, Daniel A. ;
Chang, Sam S. ;
Herrell, S. Duke ;
Penson, David F. ;
Resnick, Matthew J. ;
Smith, Joseph A. ;
Clark, Peter E. .
BJU INTERNATIONAL, 2016, 117 (02) :260-265
[10]   Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma [J].
Matrana, Marc R. ;
Atkinson, Bradley ;
Jonasch, Eric ;
Tannir, Nizar M. .
CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (03) :189-198